<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Context-Specific Duration: Adjuvant Fixed 1-Year vs Metastatic Response/biomarker-Adapted - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-34</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-34</p>
                <p><strong>Name:</strong> Context-Specific Duration: Adjuvant Fixed 1-Year vs Metastatic Response/biomarker-Adapted</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of the optimal duration of anti-PD-1 immunotherapy for melanoma, and whether it differs by depth of response, based on the following results.</p>
                <p><strong>Description:</strong> The optimal anti-PD-1 duration differs by clinical context. In the adjuvant setting (resected stage II–III/IV), a fixed 1-year course is effective and standard; extending beyond one year is unproven and may not rescue on-treatment-resistant biology. In unresectable/metastatic disease, duration should be individualized by depth of response and functional remission rather than fixed time alone.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Law 0</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Law 1</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 2: Law 2</h3>
            <p><strong>Statement:</strong> None</p>
            <p><strong>Domain/Scope:</strong> <span class="empty-note">Not specified.</span></p>
            <h4>Special Cases</h4>
            <h4>Supporting Evidence for this Law</h4>
<p class="empty-note">No evidence provided.</p>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> unknown</p>
        <p><strong>Explanation:</strong> No explanation provided.</p>
        <p><strong>References:</strong> <span class="empty-note">No references provided.</span>            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>Adjuvant extension beyond 1 year will not materially improve DMFS compared with 1-year standard in stage III disease but will increase cumulative toxicity.</li>
                <li>Neoadjuvant response-adapted strategies (pCR/MPR) that de-escalate adjuvant therapy will achieve RFS comparable to or better than upfront surgery + 1-year adjuvant in randomized settings (as NADINA suggests).</li>
                <li>In metastatic practice, adopting PET/biopsy/ctDNA to guide early stop will reduce total PD-1 exposure by ≥6 months in ≥30% of treated patients without loss of 2-year PFS.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Adjuvant ctDNA-negative status after surgery may allow shorter adjuvant PD-1 (<1 year) without loss of RFS in selected patients.</li>
                <li>A 6-month adjuvant course in ultra-high-risk stage III with negative ctDNA may be non-inferior to 12 months; requires randomized validation.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If adjuvant extension trials demonstrate significant RFS/OS benefit beyond 1 year with acceptable toxicity, the fixed 1-year law must be revised.</li>
                <li>If metastatic randomized trials show non-inferiority of universal 12-month stop versus adapted/extended strategies, the adaptation advantage is refuted.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Optimal adjuvant duration in stage IV NED after complete metastasectomy is not directly addressed here. <a href="../results/extraction-result-84.html#e84.3" class="evidence-link">[e84.3]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>